Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | CBFB | Q13951 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460819 | 0.85 | FFAR1 (0.39) | HTR2CGRM5CBFB | |
| SCHEMBL1460837 | 0.84 | CYP19A1 (0.41) | — | |
| SCHEMBL1459960 | 0.84 | HCRTR1 (0.38) | GRM5CBFBHCRTR1HCRTR2 | |
| SCHEMBL1458803 | 0.83 | HCRTR1 (0.37) | GRM5CBFBHCRTR1HCRTR2 | |
| SCHEMBL1460276 | 0.78 | MMP13 (0.36) | HTR2CCBFB | |
| SCHEMBL1459161 | 0.78 | CYP19A1 (0.43) | CDC7 | |
| SCHEMBL1459544 | 0.77 | HTR2C (0.47) | HTR2CGRM5CBFBHTR2A | |
| SCHEMBL1459683 | 0.75 | CSNK1D (0.38) | — | |
| SCHEMBL1463443 | 0.74 | STIM1 (0.44) | CDC7 | |
| SCHEMBL1463484 | 0.73 | MMP2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | HTR2C 164/4885GRM5 545/4885CBFB 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.